Teva Pharmaceutical Industries Limited, a renowned pharmaceutical company, boasts a robust product portfolio that encompasses generic medicines, specialty medicines, and biopharmaceutical products. The company caters to customers in North America, Europe, Israel, and other international markets, and offers a diverse range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. Teva Pharmaceutical Industries Limited's operations extend beyond manufacturing and selling active pharmaceutical ingredients; the company also delivers contract manufacturing services and operates an out-licensing platform that offers a wide array of products to other pharmaceutical companies. The company places a significant emphasis on the central nervous system (CNS), pain, respiratory, and oncology areas, and boasts a wide range of products and treatments in these therapeutic fields. In the CNS category, Teva Pharmaceutical Industries Limited can attribute notable contributions to Copaxone, AJOVY, and AUSTEDO, which offer relief from relapsing forms of multiple sclerosis, provide preventative relief for migraines, and offer treatment for neurodegenerative and movement disorders like those caused by Huntington's disease and tardive dyskinesia, respectively. Meanwhile, the company's range of respiratory treatments includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all geared towards helping patients suffering from asthma and chronic obstructive pulmonary disease (COPD). Notably, the oncology therapeutic field is home to some of the company's most innovative and life-changing drugs, such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. In an effort to remain at the forefront of pharmaceutical innovation, Teva Pharmaceutical Industries Limited has entered into a collaborative agreement with MedinCell to work on the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company has been in operation since 1901 and is headquartered in Tel Aviv, Israel.